Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Most Covid stocks seem to be struggling today, despite 1000+ deaths and 60,000+ new cases yesterday... oil and supermarkets fine though!!
I guess just usual AIM drift down on no news, but too risky to trade as anything could drop at any time:
- 1st patient dosed UK
- 1st patient dosed US or international
- explanation of delay (hopefully another tweek to parameters to allow faster approval and speed to market)
- home trial fully dosed
- emergency use
- pre-orders coming in
- T/O or licensing deal
- something bad (always a possibility I'm afraid)
Anyway, as usual patence is key any of the above could have a massive impact on the SP... which has held up remarkably well this week.
GLA
Todays price is not that important, but hopefully this will be the start of a sustained rise to where we should be before results of the P3 are announced... around £3.60.
With the Yanks on board filling numbers over there will be quick, and when they start to see how many lives are being saved emergency approval will follow quickly... then everyone else will follow suit and BOOM £10+.
I agree, although I think any RNS with details of phase III start or any other good news will only give a short lived rise, as recent investors will use the spike to get out. I'm also here since April and in for the long haul.
PR (Public Relations) is not needed, Synairgen will not be selling to the public. What is needed is awareness and confidence of the scientific and medical community. They are the ones that advise governments and big pharmas what and how much to buy. I believe Synairgen do already have this, and they are all eagerly waiting for further results before showing their cards.
Typical PR = "exaggerated news headlines that will inflate the short-term share price and encourage FOMO investors to jump in (and then quickly out)." I don't think this is good for the LTH's here.
Ultimately the only long-term driver for the share price will be selling the product for a profit, this will take time but IMO will be massive when it does eventually deliver... it will be worth the wait!!
Having been invested since April I have to say that I am a lot more relaxed than I was back then. We were waiting to see if SNG001 actually worked, and if it didn't would have been lucky to see the share price at 10p. Now WE KNOW IT WORKS, so not a case of IF it will start generating revenue but WHEN. And when it does it will be big... order for 1st month supply = £300,000,000!!
I see a big difference with the comments from recent investors, understandably. If I had bought in at £2+ and was expecting an immediate lift-off I would be worried. So I say "be patient and you will be rewarded" OR "Sell up now because it may go lower".
After attending the Webinar I have changed my stance slightly... in terms of timescales but not £££ expectations. It is clear from what RM said that the demand for the product will not depend on anything other than the quality of the data proving beyond a shadow of a doubt that SNG001 works for COVID and many other illnesses. IF proven then the demand will massively outstrip supply (short term). The massive ($3.6bn pa) revenues this will generate will enable supply to be ramped up, in-turn increasing revenue.
I for one think we have the best people in place to give us the data that will move this product and company in to the big league (if it isn't swallowed up beforehand). And am happy to wait!!
Wouldn't it be good to hear:
1. AstraZeneca bought all placement shares
2. Next move is full TO with Marsden, Holgate etc. to get a place at the table
3. Shareholders to receive 1 AZN share per SNG share held
Dreaming maybe... but £80m is a drop in the ocean for them in return for a world beating drug that will have massive demand long into the future, issuing another 150m shares for us lot isn't going to dilute their stash much and the SNG scientists will see their baby reach the market and beyond in the hands of the big boys.